Abstract
The effective reproductive number Re is a key indicator of the growth of an epidemic. Since the SARS-CoV-2 pandemic started, many methods and online dashboards have sprung up to monitor this number. However, these methods are not always thoroughly tested or are applied only to a limited geographic range. Here, we present a method for near real time monitoring of Re, applied to epidemic data from 170 countries. We thoroughly validate the method on simulated data, and present an intuitive web interface for interactive data exploration. We show that in the majority of countries the estimated Re dropped below 1 only after the introduction of major non-pharmaceutical interventions. For Europe, Asia, and North America we found that the implementation of non-pharmaceutical interventions was associated with reductions in the effective reproductive number. Globally, we found that relaxing non-pharmaceutical interventions did not fully revert Re values to their original levels. Generally, our framework is useful both to inform governments and the general public on the status of the epidemic in their country, as well as a source for detailed comparison between countries and in relation to local public health policies and external covariates such as mobility, behavioural, or weather data.
Significance statement During the SARS-CoV-2 pandemic, governments need a way to monitor the epidemiological situation in their country. A key indicator is the effective reproductive number Re. It describes the average number of secondary infections caused by a primary infected individual. Here, we present a method to estimate Re from case report data. We thoroughly validate the method on simulated data, and present Re estimates for 170 countries on an interactive web interface. We then use this method to investigate the impact of non-pharmaceutical interventions on reducing Re worldwide. We find that the estimated Re was significantly above 1 prior to the introduction of major non-pharmaceutical interventions, and that relaxing these interventions does not fully revert Re estimates to their prior levels.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JSH was funded by the NRP72 SNF grant (407240-167121) awarded to SB and TS. SB and TS thank ETH Zurich for funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethics commitee was involved as no clinical trial data was used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code and data is publicly available except for the line list of Swiss cases provided by the Federal Office of Public Health (we could not obtain permission to publish this data)
